eTheRNA is developing vaccines against respiratory viruses, including SARS-CoV-2, Malaria and HIV. Based on our mRNA/TriMix technology we focus on developing vaccines to promote B cell but also T cell immune responses. For our antiviral vaccines, we include conserved immunogenic epitopes to provide protection against future variations of the virus. The mRNA of the vaccines is formulated in proprietary LNPs that are delivered intramuscularly. These LNPs have favourable thermostability properties to reduce supply chain costs and increase opportunities for lower healthcare economies.

Additionally, for the convenience of patients and practitioners, we are working on an mRNA-formulation that can be administered needle-free, via intranasal administration.